You can buy or sell GBT and other stocks, options, ETFs, and crypto commission-free!
Global Blood Therapeutics, Inc. Common Stock, also called Global Blood Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Read More It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Stock Price, News, & Analysis for Global Blood Therapeutics
Media coverage about GBT stock has trended positive this week, according to InfoTrie. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Global Blood Therapeutics earned a daily sentiment score of 2.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that rec...
Expected May 7, After Hours